On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON ...
Beam Therapeutics has presented the first clinical data on its base editing technology. | Beam Therapeutics has presented the ...
Fintel on MSN7d
Leerink Partners Upgrades Beam Therapeutics (BEAM)Fintel reports that on November 6, 2024, Leerink Partners upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from ...
Leerink Partners has recently raised Beam Therapeutics Inc (BEAM) stock to Outperform rating, as announced on November 6, 2024, according to Finviz. Earlier, on October 16, 2024, Scotiabank had ...
Beam Therapeutics (BEAM) stock falls as patient dies after receiving the company's gene editing therapy.in an early-stage ...
H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on BEAM stock, giving a Buy rating today. Patrick Trucchio has ...
Beam Therapeutics’ experimental gene-editing therapy for sickle cell disease now has its first cut of patient data showing signs of treating the rare blood disorder in a way that could ...
Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report)’s share price gapped down before the market opened on Tuesday after the company announced weaker than expected quarterly earnings. The stock ...
Analysts estimate that Beam Therapeutics will report an earnings per share (EPS) of $-1.16. The announcement from Beam Therapeutics is eagerly anticipated, with investors seeking news of surpassing ...
Check the time stamp on this data. Updated AI-Generated Signals for Beam Therapeutics Inc. (BEAM) available here: BEAM.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback